Figure 2.
Probability of occurrence of grade III/IV rash or hepatotoxicity during the three months of follow-up in women initiating a nevirapine-based antiretroviral therapy according to the period of the initiation of treatment (pregnant and non pregnant women) . MTCT-Plus program in Abidjan, Côte d'Ivoire